Input | Δ Costs (€) | Δ LY | Δ QALY | ICER (€/LY) | ICUR (€/QALY) |
---|---|---|---|---|---|
Base case scenario | 3549 | 0.475 | 0.384 | 7473 | 9246 |
Model settings | |||||
Discount rate 0% | 3733 | 0.494 | 0.399 | 7551 | 9347 |
Discount rate 5% | 3436 | 0.463 | 0.374 | 7423 | 9181 |
Time horizon 28 days | − 666,50 | 0.000 | 0.002 | Dominant | Dominant |
Time horizon 1 year | 717 | 0.164 | 0.135 | 4384 | 5316 |
Alternative patients’ demographic characteristics* | 3247 | 0.433 | 0.350 | 7491 | 9269 |
Utility Values + 20% | 3549 | 0.475 | 0.457 | 7473 | 7758 |
Utility Values −20% | 3549 | 0.475 | 0.307 | 7473 | 11,558 |
Calibration of effectiveness | |||||
Long-term care (50%) | 9499 | 0.475 | 0.356 | 20,004 | 26,691 |
Mortality after 28 days + 20% | 3025 | 0.423 | 0.342 | 7154 | 8833 |
Mortality after 28 days −20% | 4150 | 0.535 | 0.431 | 7762 | 9622 |
Calibration of costs | |||||
Hospitalisation costs € 4981.23 | 2878 | 0.475 | 0.384 | 6061 | 7500 |
RRT costs + 20% | 3697 | 0.475 | 0.384 | 7786 | 9634 |
RRT costs −20% | 3400 | 0.475 | 0.384 | 7160 | 8859 |
Vials sharing | 3784 | 0.475 | 0.384 | 7968 | 9859 |
Follow-up costs after home discharge € 87.41 | 3560 | 0.475 | 0.384 | 7497 | 9276 |